ndc for semaglutide Rx Item-Wegovy 0.25Mg/0.5 Inj 4X0.5 By Novo Nordisk USA It is used by certain overweight people Diabetes advocacy group discourages use

For example, clinical data shows that semaglutide may reduce cardiovascular risk in persons with T2D and other cardiometabolic disorders

endocrine disease (Type 1 diabetes, hyperthyroidism, hypothyroidism)

Pharmacokinetic data indicate that fasting plasma glucose (FPG) levels begin to decrease within two weeks, and steady-state plasma concentrations are typically achieved after six weeks of weekly dosing [59]

Another advantage of Tirzepatide is its potential to further improve insulin sensitivity, making it especially beneficial for individuals with insulin resistance or those at risk of developing type 2 diabetes

Esto contribuye a una disminucin de los niveles de glucosa en sangre, mejorando as el control glucmico en pacientes con diabetes tipo 2